PBL to Develop an Affinity Ligand for Purification of Novartis Vaccine
Company will screen its Chemical Combinatorial Libraries.!--h2>
ProMetic Biosciences (PBL) will develop a synthetic ligand affinity adsorbent for the purification of Novartis’ new vaccine product currently in clinical trials.
Under the terms of the agreement Novartis will fund PBL to screen its Chemical Combinatorial Libraries® for ligands suitable for the processs-cale purification of its recombinant protein vaccine. The work will be conducted at PBL's research laboratories in Cambridge Science Park, U.K.
PBL states that owing to their high selectivity, robustness, and low cost compared to ligands derived from biological sources, Mimetic Ligands™ provide biopharmaceutical manufacturing companies with numerous advantages, particularly for large-scale production of price-sensitive products.